Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial.

Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial. J Am Coll Cardiol. 2020 05 12; 75(18):2297-2308.

View in: PubMed

subject areas

Acute Coronary Syndrome
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized
Cholesterol, LDL
Cost-Benefit Analysis
Double-Blind Method
Drug Therapy, Combination
Female
Humans
Hypercholesterolemia
Male
Middle Aged
Treatment Outcome

authors with profiles

Robert Harrington